<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044928</url>
  </required_header>
  <id_info>
    <org_study_id>0910X-101074</org_study_id>
    <nct_id>NCT00044928</nct_id>
  </id_info>
  <brief_title>Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection</brief_title>
  <official_title>Randomized, Open-label, Comparative Study of Zosyn (Pip/Tazo [12g/1.5g]) Administered by Daily 24hr Continuous Infusion vs Zosyn (Pip/Tazo) [3g/0.375g]) q6h for the Treatment of Hospitalized Patients With Complicated Intra-abdominal Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      A Phase IV, multicenter study of hospitalized patients with complicated intra-abdominal
      infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">262</enrollment>
  <condition>Bacterial Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/Tazobactam</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Written informed consent will be obtained prior to enrollment into the study. If any
             patient is unable to give consent, it may be obtained from next of-kin or a legal
             representative if in accordance with local laws and regulations

          -  Hospitalized, ≥18 years of age

          -  Male or non-pregnant, non-lactating female who is post-menopausal, surgically
             sterilized or is using birth control pills, contraceptive implant or injection (ex:
             NORPLANT®; DEPO-PROVERA®), intra-uterine device, barrier methods with spermicide, or
             abstinence. (Effective contraception should have been in place for at least two months
             prior to study entry and must continue for at least 30 days after treatment
             discontinuation)

        Exclusion Criteria

          -  Patients with underlying immunodeficiency disease or patients requiring chronic
             treatment with known immunosuppressant medications including &gt;5mg/day prednisone

          -  Active or treated leukemia, or systemic malignancy that required treatment with
             chemotherapy, immunotherapy, radiation therapy, or antineoplastic therapy within the
             past year or which is anticipated to begin prior to the Test-of-Cure visit; or any
             known or suspected malignancy to the abdomen

          -  Concurrent hemodialysis, peritoneal dialysis or patients with indwelling peritoneal
             catheters or shunts, plasmapheresis or hemoperfusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>September 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2002</study_first_posted>
  <last_update_submitted>February 7, 2013</last_update_submitted>
  <last_update_submitted_qc>February 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abdominal Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

